GGrantIndex
← Leaderboards

Bruce E Clurman

Fred Hutchinson Cancer Research Center

$16,275,505
Attributed
$18,328,588
Total exposure
8
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$18,328,588 · 8

By mechanism

R01$15,635,085 · 6
P01$2,272,423 · 1
R21$421,080 · 1

Top collaborators

Most similar at Fred Hutchinson Cancer Research Center

Same institution · by research overlap

Others in their field

Top investigators on “Mutation

Research focus

MutationPathway InteractionsGenesTumor Suppressor ProteinsPhosphorylationProteinsCellsTumorigenesisMalignant NeoplasmsNormal CellOncogenicPhysiologicalCancer TherapyBaseCyclin EMutateBinding (Molecular Function)Cancer CellCell CycleNotch ProteinCell DivisionExhibitsPhosphotransferasesIn Vivo

Grant awards (50)

The Fbw7 ubiquitin ligase network: normal and neoplastic functions$496,612
R01 · FY2025 · CA · contact PI
The Fbw7 ubiquitin ligase network: normal and neoplastic functions$468,313
R01 · FY2024 · CA · contact PI
The Fbw7 ubiquitin ligase network: normal and neoplastic functions$463,014
R01 · FY2023 · CA · contact PI
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer$234,777
R01 · FY2021 · CA · contact PI
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer$166,708
R01 · FY2021 · CA · contact PI
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer$401,486
R01 · FY2020 · CA · contact PI
CDK2 and Cancer: Mechanisms and Opportunities$353,925
R01 · FY2020 · CA · contact PI
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer$389,319
R01 · FY2019 · CA · contact PI
CDK2 and Cancer: Mechanisms and Opportunities$343,308
R01 · FY2019 · CA · contact PI
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer$399,129
R01 · FY2018 · CA · contact PI
CDK2 and Cancer: Mechanisms and Opportunities$353,925
R01 · FY2018 · CA · contact PI
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer$415,275
R01 · FY2017 · CA · contact PI
CDK2 and Cancer: Mechanisms and Opportunities$409,815
R01 · FY2017 · CA · contact PI
CDK2 and Cancer: Mechanisms and Opportunities$428,815
R01 · FY2016 · CA · contact PI
Identifying CDK4 and CDK6 substrates in cancers and cancer therapy$191,400
R21 · FY2016 · CA · contact PI
Developing Ubiquitin Ligase Agonists as Cancer Therapeutics$507,502
R01 · FY2015 · CA · contact PI
Identifying CDK4 and CDK6 substrates in cancers and cancer therapy$229,680
R21 · FY2015 · CA · contact PI
Tumor Suppression by the Fbw7 Ubiquitin Ligase$79,693
R01 · FY2015 · CA · contact PI
Developing Ubiquitin Ligase Agonists as Cancer Therapeutics$460,606
R01 · FY2014 · CA · contact PI
Tumor Suppression by the Fbw7 Ubiquitin Ligase$343,671
R01 · FY2014 · CA · contact PI
Developing Ubiquitin Ligase Agonists as Cancer Therapeutics$462,467
R01 · FY2013 · CA · contact PI
Normal and Neoplastic Regulation of Cyclin E$348,714
R01 · FY2013 · CA · contact PI
Tumor Suppression by the Fbw7 Ubiquitin Ligase$333,042
R01 · FY2013 · CA · contact PI
Normal and Neoplastic Regulation of Cyclin E$370,973
R01 · FY2012 · CA · contact PI
Tumor Suppression by the Fbw7 Ubiquitin Ligase$354,300
R01 · FY2012 · CA · contact PI
Cell Proliferation and Differentiation By the Fbw 7 Tumor Suppressor$452,634
P01 · FY2011 · HL · contact PI
Normal and Neoplastic Regulation of Cyclin E$370,973
R01 · FY2011 · CA · contact PI
Tumor Suppression by the Fbw7 Ubiquitin Ligase$354,300
R01 · FY2011 · CA · contact PI
Cell Proliferation and Differentiation By the Fbw 7 Tumor Suppressor$451,148
P01 · FY2010 · HL · contact PI
Normal and Neoplastic Regulation of Cyclin E$382,446
R01 · FY2010 · CA · contact PI
Tumor Suppression by the Fbw7 Ubiquitin Ligase$365,258
R01 · FY2010 · CA · contact PI
Cell Proliferation and Differentiation By the Fbw 7 Tumor Suppressor$455,545
P01 · FY2009 · HL · contact PI
Normal and Neoplastic Regulation of Cyclin E$382,446
R01 · FY2009 · CA · contact PI
Mechanisms of Cell Cycle Associated Neoplasia$348,574
R01 · FY2009 · CA · contact PI
Cell Proliferation and Differentiation By the Fbw 7 Tumor Suppressor$448,286
P01 · FY2008 · HL · contact PI
Mechanisms of Cell Cycle Associated Neoplasia$348,574
R01 · FY2008 · CA · contact PI
Cell Proliferation and Differentiation By the Fbw 7 Tumor Suppressor$464,810
P01 · FY2007 · HL · contact PI
Normal and Neoplastic Regulation of Cyclin E$364,978
R01 · FY2007 · CA · contact PI
Mechanisms of Cell Cycle Associated Neoplasia$348,574
R01 · FY2007 · CA · contact PI
Normal and Neoplastic Regulation of Cyclin E$375,879
R01 · FY2006 · CA · contact PI
Mechanisms of Cell Cycle Associated Neoplasia$358,985
R01 · FY2006 · CA · contact PI
Normal and Neoplastic Regulation of Cyclin E$384,925
R01 · FY2005 · CA
Mechanisms of Cell Cycle Associated Neoplasia$367,625
R01 · FY2005 · CA
Normal and Neoplastic Regulation of Cyclin E$384,925
R01 · FY2004 · CA
MECHANISMS OF P27KIPL-ASSOCIATED NEOPLASIA$334,264
R01 · FY2004 · CA
Normal and Neoplastic Regulation of Cyclin E$384,925
R01 · FY2003 · CA
MECHANISMS OF P27KIPL-ASSOCIATED NEOPLASIA$301,190
R01 · FY2003 · CA
MECHANISMS OF P27KIPL-ASSOCIATED NEOPLASIA$292,422
R01 · FY2002 · CA
MECHANISMS OF P27KIPL-ASSOCIATED NEOPLASIA$304,575
R01 · FY2001 · CA
MECHANISMS OF P27KIPL-ASSOCIATED NEOPLASIA$293,858
R01 · FY2000 · CA